Following the above, the Company's Board of Directors approves Hevron Capital’s to extend the "No-Shop" period until May 20, 2022 subject to the approval of the Company’s bondholders’ .
Disappointingly we still await bondholders approval perhaps at Plaza
Maxify Solutions seems to be taking quite a while to re-list on the NASDAQ as promised.
Although a tiny Invest in Midatech Pharma has done well this week , with good news ;
its development programme of MTX110 for the treatment of recurrent glioblastoma has been granted Fast Track designation by the FDA agency.
HPAC 5K
AIQ 1KRUR 3K
Others 1K
Yinn looks good value at $90
Although , the long weekend has been clipped by work . One hopes the oncoming months provide the expected results .
Outstanding
No comments:
Post a Comment